In an unprecedented event, a health research regulatory agency in the United States has granted approval to a biotech company that eyes to investigate whether a dead human brain could be brought to life again.
The multi-level study, which was dubbed the ReAnima Project, aims to determine whether a human brain can be brought to life after it was declared clinically dead; that is, after it loses its vital function. To do this, researchers from Bioquark Inc. will administer several therapies to the brains of the dead, which will be observed for six months, the Telegraph reported.
After the ethical review board of the National Institute of Health in the U.S. and India, where the first phase of the study will be conducted, Bioquark will now proceed with the study’s first state, the “First In Human Neuro-Regeneration & Neuro-Reanimation.”
Part of the study’s initial stage is the recruitment of 20 patients who have died of traumatic brain injuries and are declared clinically dead. In order to test the brain’s regenerative powers, researchers will administer two types of therapies, including stem cells and cocktails of peptides.
Lasers and nerve stimulation, which are proven effective in bringing coma patients into consciousness, will be administered throughout the six-month duration of the study.
Dr Ira Pastor, Bioquark Inc.’s CEO, told the Telegraph that the NIH’s ethical approval is the first step of the complex study. She said that the entire research team is expecting a lot of hindrances along the way, especially in recruiting families who will allow their deceased loved ones to be part of the study.
“To undertake such a complex initiative, we are combining biologic regenerative medicine tools with other existing medical devices typically used for stimulation of the central nervous system, in patients with other severe disorders of consciousness,” Pastor told the Telegraph.